SynthesisJournal of the American Heart Association2025
Systematic Review of the Differential Effects of TGF-β1 in Ischemic and Hemorrhagic Preclinical Stroke Models.
Synthesis in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Astrocyte-Microglia Crosstalk in Post-Hemorrhagic Neurovascular Microenvironment: Mechanistic Nodes, Cross-Stroke Comparisons, and Therapeutic Reprogramming.Translational stroke research · 2026Review
- Pathogenic role of serpin B3-positive neutrophils in reinforcing thrombus stiffening during ischemic stroke.Blood · 2026Article
- Sex differences in proteomic response to ischemic stroke.Biology of sex differences · 2026Article
- Steric hindrance-mediated extracellular vesicle size fractionation for rapid prehospital diagnosis of intracerebral hemorrhage.Nature communications · 2026Article
- An integrative clinical and bioinformatic analysis identifies MicroRNAs as biomarkers of ischemic stroke severity.Scientific reports · 2026Article
- Aerobic Exercise-Induced TGF-β Receptor Reprogramming Disrupts Neutrophil-Microglia Crosstalk to Attenuate Early Brain Injury after Subarachnoid Hemorrhage.Research (Washington, D.C.) · 2026Article
- Article
- Adult organotypic brain slice cultures recapitulate extracellular matrix remodeling in hemorrhagic stroke.Frontiers in cellular neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundStroke is a leading cause of death, with patients often experiencing significant disability. Stroke is classified as ischemic, caused by the occlusion of a blood vessel leading to reduction in cerebral blood flow, or hemorrhagic, resulting from the rupture of a vessel that causes bleeding into the brain. Transforming growth factor β1 (TGF-β1), a pleiotropic cytokine, has been investigated in stroke due to its diverse effects on proliferation, extracellular matrix deposition, and inflammation. This systematic review examined the role of TGF-β1 in preclinical studies of ischemic and hemorrhagic stroke.
methodsA search of PubMed, Web of Science, and Scopus databases identified animal studies examining TGF-β1 signaling as an outcome or intervention. A total of 89 studies were included: 68 on ischemic stroke and 21 on hemorrhagic stroke. Studies were assessed for bias following the SYRCLE (Systematic Review Centre for Laboratory Animal Experimentation) guidelines, followed by extraction of methodology and the role of TGF-β1.
resultsCompliance with SYRCLE guidelines was found to be low, and the methodological approaches to stroke models were variable. A range of interventions were shown to modify TGF-β1 expression or signaling, with exogenous TGF-β1 improving outcomes in all ischemic stroke studies. TGF-β1 was found to play a protective role in 76% of ischemic stroke studies but was only protective in 33% of hemorrhagic stroke studies, with likely involvement in fibrosis development in the latter.
conclusionsOur findings suggest a marked difference in TGF-β1 function between these types of stroke, and it is hypothesized that blood cytotoxicity following hemorrhagic stroke may generate more sustained TGF-β1 expression than that seen in ischemic stroke. This may lead to TGF-β1-mediated fibrosis and hydrocephalus, as opposed to the neuroprotective role played by the same molecule following ischemic stroke. These findings highlight the possible clinical utility of exogenous TGF-β1 therapies after ischemic stroke, and TGF-β1 inhibitors after hemorrhagic stroke, to reduce morbidity and disability caused by these events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.